StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

StockNews.com began coverage on shares of Oragenics (NYSE:OGENGet Rating) in a research report issued on Thursday. The brokerage set a “hold” rating on the stock.

OGEN stock opened at $0.31 on Thursday. The stock’s 50 day simple moving average is $0.36. The stock has a market capitalization of $36.64 million, a PE ratio of -2.25 and a beta of 0.12. Oragenics has a fifty-two week low of $0.30 and a fifty-two week high of $1.15.

Oragenics (NYSE:OGENGet Rating) last posted its earnings results on Thursday, March 24th. The company reported ($0.02) earnings per share for the quarter. The company had revenue of $0.09 million during the quarter.

Oragenics Company Profile (Get Rating)

Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Further Reading

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.